Q-Line Biotech Limited is gearing up to make its stock market debut through an SME IPO on the NSE Emerge platform, looking to raise approximately ₹214.48 crore entirely through a fresh issue of 62,53,200 equity shares. The issue is a 100% book-built offering at a price band of ₹326 to ₹343 per share. Investors can place their bids starting Thursday, May 21, 2026, with the subscription window open through Monday, May 25, 2026.
Allotment is expected to be finalised by May 26, 2026, with listing scheduled on NSE SME on May 29, 2026. Application lots are fixed at 400 shares each. Retail participants can place bids only from the minimum investment threshold onward of two lots 800 shares amounting to ₹2,74,400 at the upper price band. For HNI investors, bidding starts from three lots (1,200 shares), requiring a minimum commitment of ₹4,11,600.
Q-Line Biotech IPO Details
The key issue parameters for the Q-Line Biotech IPO are outlined in the table below.
| Particulars | Details |
| Bidding Opens | May 21, 2026 |
| Bidding Closes | May 25, 2026 |
| Issue Type | Book Building Issue |
| Face Value | ₹10 per share |
| Price Band | ₹326 to ₹343 per share |
| Listing at | NSE Emerge (SME) |
| Lot Size | 400 Shares |
| Reserved for Market Maker | Hem Finlease Pvt. Ltd. |
| Offer for Sale(OFS) | Nil |
| Fresh Issue | 62,53,200 shares (₹214.48 Crore) |
| Total Issue | 62,53,200 shares (₹214.48 Crore) |
| Minimum Investment | ₹2,74,400 (800 shares / 2 lots) |
Q-Line Biotech IPO Timeline
Presented here is the anticipated sequence of events for the IPO.
| Particulars | Details |
| Bidding Opens | May 21, 2026 |
| Bidding Closes | May 25, 2026 |
| Allotment Expected | May 26, 2026 |
| Refunds / Unblocking of ASBA | May 27, 2026 |
| Share Credit to Demat | May 27, 2026 |
| Listing Scheduled | May 29, 2026 |
| Cut-off for UPI Mandate | 5:00 PM on May 25, 2026 |
Q-Line Biotech Limited Key Performance Indicators (KPI)
The table below captures the company’s financial KPIs as per its consolidated restated financial statements.
| KPIs | Dec 31, 2025 | FY25 | FY24 |
| ROE (%) | 16.88% | 23.74% | 21.29% |
| ROCE (%) | 13.32% | 17.66% | 19.25% |
| Debt Equity (times) | 1.06 | 0.87 | 0.60 |
| RoNW (%) | 16.88% | 23.74% | 21.29% |
| PAT Margin (%) | 16.65% | 8.97% | 16.92% |
| EBITDA Margin (%) | 27.64% | 22.73% | 18.48% |
| Price Book Value | [●]* | [●]* | [●]* |
Q-Line Biotech Limited Financials
The consolidated restated financial performance of the company across the most recent periods is presented below.
| Particulars (in ₹ Lakhs) | Dec 31, 2025 | FY25 | FY24 |
| Revenue from Operations | 23,242.03 | 31,378.04 | 20,364.61 |
| Other Income | 408.22 | 880.38 | 280.20 |
| Total Income | 23,650.25 | 32,258.42 | 20,644.81 |
| Profit After Tax | 3,869.39 | 2,813.09 | 3,444.47 |
| Total Borrowings | 24,385.48 | 16,494.98 | 9,690.00 |
Q-Line Biotech IPO Subscription Status
The Q-Line Biotech IPO shares subscription status is as follows:
| Date | QIB (Ex Anchor) | NII* | NII (> ₹10L) | NII (< ₹10L) | Individual Investors | Total |
|---|---|---|---|---|---|---|
| May 21 (Day 1) | 4.15 | 5.26 | 5.85 | 4.08 | 3.71 | 4.17 |
| May 22 (Day 2) | 5.19 | 15.62 | 17.96 | 10.95 | 10.07 | 9.87 |
| May 25 (Day 3) | 13.86 | 70.15 | 86.05 | 38.35 | 36.01 | 37.00 |
Q-Line Biotech IPO Grey Market Premium
As per the latest data as of 21 May, 2026 the current GMP for Q-Line Biotech IPO stands at ₹120 pointing to an estimated listing price of approximately ₹463 per share. This indicates positive but measured sentiment in the unofficial market ahead of the issue opening.
| GMP Date | GMP | Est. Listing Price | Est. Profit* | Last Updated |
|---|---|---|---|---|
| 25-05-2026 Close | ₹125 ─ | ₹468 (36.44%) | ₹50,000 | 25-May-2026 11:36 |
| 24-05-2026 | ₹125 ▼ | ₹468 (36.44%) | ₹50,000 | 24-May-2026 23:36 |
| 23-05-2026 | ₹127 ─ | ₹470 (37.03%) | ₹50,800 | 23-May-2026 23:34 |
| 22-05-2026 | ₹127 ▲ | ₹470 (37.03%) | ₹50,800 | 22-May-2026 23:34 |
| 21-05-2026 Open | ₹117 ▼ | ₹460 (34.11%) | ₹46,800 | 21-May-2026 23:33 |
| 20-05-2026 | ₹141 ▲ | ₹484 (41.11%) | ₹56,400 | 20-May-2026 23:37 |
| 19-05-2026 | ₹110 ▲ | ₹453 (32.07%) | ₹44,000 | 19-May-2026 23:32 |
| 18-05-2026 | ₹69 ▲ | ₹412 (20.12%) | ₹27,600 | 18-May-2026 23:34 |
Note: Grey Market Premium operates outside formal exchange mechanisms and serves only as a rough indication of prevailing market sentiment.
Q-Line Biotech IPO Reservation
The issue allocation framework across investor categories is provided below.
| Investor Category | Reservation |
| Market Maker Shares | 3,13,200 |
| QIB Shares | Not more than 50% of Net Issue |
| NII (HNI) Shares | Not less than 15% of Net Issue |
| Retail Shares | Not less than 35% of Net Issue |
| Anchor Investor Portion | Up to 60% of QIB Portion (discretionary) |
| Total Shares | 62,53,200 |
Q-Line Biotech IPO Lot Size
Details regarding the smallest permissible application size are given below.
| Application | Lots | Shares | Amount |
| Retail (Min) | 2 | 800 | ₹2,74,400 |
| Retail (Max) | 2 | 800 | ₹2,74,400 |
| S-HNI (Min) | 3 | 1,200 | ₹4,11,600 |
| S-HNI (Max) | 7 | 2,800 | ₹9,60,400 |
| B-HNI (Min) | 8 | 3,200 | ₹10,97,600 |
Q-Line Biotech IPO Anchor Investors
The particulars associated with the anchor investor portion of this issue are provided herein:
| Particulars | Details |
| Anchor Investor Bidding Date | May 20, 2026 |
| Anchor Portion Size | Up to 60% of QIB Portion |
| 50% Lock-in Period | 30 days from allotment |
| Remaining 50% Lock-in Period | 90 days from allotment |
Q-Line Biotech IPO Prospectus
The following materials present detailed disclosures regarding the company and the public offering.
| Draft Red Herring Prospectus (DRHP) | |
| Red Herring Prospectus (RHP) | |
| Anchor Investors | – |
| Final Prospectus | Not Disclosed Yet |
About Q-Line Biotech Limited
The enterprise was first registered as POCT Services Private Limited in 2010 and subsequently underwent a name change to Q-Line Biotech Limited from Lucknow, UP. Over the years from 2013, the company has expanded its In-Vitro Diagnostic (IVD) offerings to include clinical testing kits, diagnostic equipment, and related healthcare products.
The company currently operates four manufacturing facilities three in Lucknow, Uttar Pradesh, and one in Bawana Industrial Area, Delhi with an aggregate installed capacity of approximately 1.4 million kits for Hematology, Clinical Chemistry Reagents, and Rapid/ELISA kits, and 1,200 Selectra Machines. A fourth unit commissioned in February 2026 will add significant capacity across Clinical Chemistry Reagents, glucometer devices, and glucometer strips. Its market presence extended to 26 states and UTs through an established distributor base of 283 partners as of Dec 31, 2025.
| Lead Manager | HEM Securities Limited and Share India Capital Services Private Limited |
| IPO Registrar | Purva Sharegistry (India) Private Limited |
Q-Line Biotech IPO Objectives
The IPO funds are expected to support operational needs while lowering existing financial obligations.
| Particulars | Amount (₹ in Lakhs) |
| For supporting general corporate operations | 9,350.00 |
| Repayment/prepayment of certain existing borrowings, in part or full | 9,000.00 |
| General corporate purposes | – |
| Total | 18,350.00 |
Strengths of Q-Line Biotech Limited
The well-defined operational and competitive strengths of the company are as follows:
- Multi-Facility Manufacturing Setup with Dedicated Research Operations: The business has built manufacturing infrastructure in Lucknow and Delhi with support from a 19-member innovation and engineering team. R&D spend runs at approximately 1% of revenue, focused on prototyping, reverse engineering, and product validation. ISO 13485:2016 certification at its Lucknow facility reflects its quality commitment.
- Widespread Distribution Network: As of March 31, 2026, the company has 103 sales personnel, 35 service engineers, and 283 distributors covering all four regions of India.
- Long-Standing Customer Relationships: Of total customers in FY2025, 56.42% were repeat buyers. A total of 1,642 unique customers have been served across the last three financial years.
- Strong Financial Growth Track Record: Revenue grew from ₹18,273.63 lakhs in FY23 to ₹31,378.04 lakhs in FY25, a CAGR of 31.04%. EBITDA margin expanded from 18.05% in FY23 to 27.64% for the period ending December 31, 2025.
- Experienced Promoter and Management Team: Promoters bring 20 to 31 years of experience in the IVD and diagnostic sector, overseeing manufacturing, R&D, sales, and finance operations.
Risks of Q-Line Biotech Limited
Before applying to this IPO, investors should carefully evaluate the following business and sector-specific risks, which are:
- Manufacturing Disruption Risk: Four facilities concentrated in Lucknow and Delhi are exposed to equipment breakdown, power disruptions, labour disputes, and regulatory non-compliance any of which could materially impact output and financials.
- Raw Material and Import Dependency: Over 54% of procurement for the period ending December 31, 2025 was imported from countries including Sweden, France, Spain, China, and South Korea. Supply disruptions or geopolitical developments could significantly impact costs.
- Heavy Distributor Concentration: A single group entity POCT Services contributed over 60% of sales. company derived nearly three-fourths of its revenue from its top three distribution partners.
- The top three distributors accounted for 74.72% of revenue for the period ending December 31, 2025. Loss of any key distributor relationship poses material revenue risk.
- Geographical Revenue Concentration: The Northern region contributed 81.75% of revenue for the period ending December 31, 2025. Any regional slowdown could disproportionately affect overall performance.
- Rising Debt Levels: Total debt grew from ₹7,364.84 lakhs in FY23 to ₹24,385.48 lakhs as of December 31, 2025, increasing debt servicing obligations considerably.
- Credit Rating Downgrade: The company’s CRISIL rating was downgraded in FY2025. Any further adverse revision could raise borrowing costs and tighten lending covenants, limiting financial flexibility going forward.
Q-Line Biotech IPO Review
Q-Line Biotech brings consistent revenue growth, improving margins, and an integrated IVD manufacturing model to the public markets. High distributor concentration, rising debt, and import dependency remain key risks to consider. The company saw a strong Day 1 subscription of 2.92x. A current GMP of ₹120 points to an estimated listing price of ₹463, reflecting positive unofficial market sentiment.
Other Recent IPO List
View other IPOs presently active as well as those nearing their opening dates.
| Bio Medica Laboratories IPO | Autofurnish IPO |
| SMR Jewels IPO | Yaashvi Jewellers IPO |
| Merritronix IPO | M R Maniveni Foods IPO |
| Harikanta Overseas IPO | Vegorama Punjabi Angithi IPO |
Q-Line Biotech IPO FAQs
Q-Line Biotech IPO is a 100% book-built SME issue comprising 62,53,200 fresh equity shares of face value ₹10 each, aggregating up to ₹214.48 crore. The issue is proposed to be listed on the NSE Emerge platform on May 29, 2026.
Investors can apply through ASBA-enabled net banking or UPI via their stock broker during the subscription period from May 21 to May 25, 2026. The UPI mandate cut-off is 5:00 PM on the closing date of May 25, 2026.
The company has reported consistent revenue growth at a CAGR of 31.04% between FY23 and FY25, improving EBITDA margins, and a diversified IVD product portfolio. However, high distributor concentration, rising debt levels, and heavy import dependency are important risk factors to evaluate carefully before applying.
The minimum lot size is 400 shares. Retail investors must apply for a minimum of two lots 800 shares amounting to ₹2,74,400 at the upper price band of ₹343 per share.
The basis of allotment for the Q-Line Biotech IPO is expected to be finalised on May 26, 2026, with refunds and demat credits processed on May 27, 2026.
The shares are proposed to be listed and traded on NSE Emerge from May 29, 2026.
The current Grey Market Premium for the Q-Line Biotech IPO stands at ₹120, pointing to an estimated listing price of approximately ₹463 per share. A possible listing gain of around 34.99% over the upper price band. GMP is an unofficial, unregulated indicator and should not be the sole basis for any investment decision.
